search
Back to results

Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms

Primary Purpose

Aortic Aneurysm, Thoracic

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
GORE TAG® Thoracic Endoprosthesis
Sponsored by
W.L.Gore & Associates
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Aneurysm, Thoracic

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Descending thoracic aortic aneurysm deemed to warrant surgical repair:

    1. Fusiform aneurysm greater than or equal to 2 times diameter of normal adjacent aorta
    2. Saccular aneurysm
  2. Anatomy meets GORE TAG Thoracic Endoprosthesis specification criteria as indicated in the Instructions for Use (Appendix A)
  3. Minimum 2 cm non-aneurysmal segment proximal and distal to the aneurysm

    • <60 degree angle in the aortic arch may require additional length of non-aneurysmal segment if the arch is included in the treatment segment

  4. Life expectancy > 2 years
  5. Surgical Candidate

    • ASA Class I, II, III, or IV
    • NYHA Class I, II, III or no heart disease
  6. Male or infertile female
  7. Minimum 21 years of age
  8. Able to comply with protocol requirements
  9. Signed Informed Consent Form

Exclusion Criteria:

  1. 4 mm aortic taper and inability to use devices of different diameters, to compensate for the taper, in the treatment area of the aorta
  2. Significant thrombus at the proximal or distal implantation zones
  3. Mycotic aneurysm
  4. Hemodynamically unstable aneurysm rupture (non-contained aneurysm rupture)
  5. Acute or chronic aortic dissection
  6. Planned occlusion of the left carotid or celiac arteries
  7. "Planned" concomitant surgical procedure (other than left subclavian transposition) or previous major surgery within 30 days
  8. Myocardial infarction or cerebral vascular accident within 6 weeks
  9. Severe respiratory insufficiency sufficient that precludes open thoracotomy
  10. Renal insufficiency (Creatinine > 2.0 mg/dL) with or without dialysis
  11. Degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome
  12. Participation in another investigational device or drug study within 1 year
  13. Documented history of drug abuse within 6 months

Sites / Locations

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

GORE TAG® Thoracic Endoprosthesis

Arm Description

Outcomes

Primary Outcome Measures

Aneurysm Related Death
Freedom from aneurysm related mortality for TAG 05-02 subjects

Secondary Outcome Measures

A Subset of Major Adverse Events Will be Evaluated in Subjects Treated With the TAG Device and Subjects Treated With Open Surgical Repair.
Proportion of subjects in TAG 05-02 with MAEs

Full Information

First Posted
December 20, 2007
Last Updated
August 6, 2014
Sponsor
W.L.Gore & Associates
search

1. Study Identification

Unique Protocol Identification Number
NCT00590759
Brief Title
Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms
Official Title
A Clinical Evaluation of the GORE TAG Thoracic Endoprosthesis in the Primary Treatment of Descending Thoracic Aortic Aneurysms
Study Type
Interventional

2. Study Status

Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
August 2005 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
W.L.Gore & Associates

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this post-approval study is to evaluate the long-term performance of the GORE TAG® Thoracic Endoprosthesis (TAG device) in the primary treatment of descending thoracic aortic (DTA) aneurysms

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Aneurysm, Thoracic

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GORE TAG® Thoracic Endoprosthesis
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
GORE TAG® Thoracic Endoprosthesis
Intervention Description
implant
Primary Outcome Measure Information:
Title
Aneurysm Related Death
Description
Freedom from aneurysm related mortality for TAG 05-02 subjects
Time Frame
5 years
Secondary Outcome Measure Information:
Title
A Subset of Major Adverse Events Will be Evaluated in Subjects Treated With the TAG Device and Subjects Treated With Open Surgical Repair.
Description
Proportion of subjects in TAG 05-02 with MAEs
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Descending thoracic aortic aneurysm deemed to warrant surgical repair: Fusiform aneurysm greater than or equal to 2 times diameter of normal adjacent aorta Saccular aneurysm Anatomy meets GORE TAG Thoracic Endoprosthesis specification criteria as indicated in the Instructions for Use (Appendix A) Minimum 2 cm non-aneurysmal segment proximal and distal to the aneurysm • <60 degree angle in the aortic arch may require additional length of non-aneurysmal segment if the arch is included in the treatment segment Life expectancy > 2 years Surgical Candidate ASA Class I, II, III, or IV NYHA Class I, II, III or no heart disease Male or infertile female Minimum 21 years of age Able to comply with protocol requirements Signed Informed Consent Form Exclusion Criteria: 4 mm aortic taper and inability to use devices of different diameters, to compensate for the taper, in the treatment area of the aorta Significant thrombus at the proximal or distal implantation zones Mycotic aneurysm Hemodynamically unstable aneurysm rupture (non-contained aneurysm rupture) Acute or chronic aortic dissection Planned occlusion of the left carotid or celiac arteries "Planned" concomitant surgical procedure (other than left subclavian transposition) or previous major surgery within 30 days Myocardial infarction or cerebral vascular accident within 6 weeks Severe respiratory insufficiency sufficient that precludes open thoracotomy Renal insufficiency (Creatinine > 2.0 mg/dL) with or without dialysis Degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome Participation in another investigational device or drug study within 1 year Documented history of drug abuse within 6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Morasch, M.D.
Organizational Affiliation
St. Vincent's Healthcare, Billings MT
Official's Role
Principal Investigator
Facility Information:
City
Phoenix
State/Province
Arizona
Country
United States
City
Los Angeles
State/Province
California
Country
United States
City
San Francisco
State/Province
California
Country
United States
City
Greeley
State/Province
Colorado
Country
United States
City
Gainesville
State/Province
Florida
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
Chicago
State/Province
Illinois
Country
United States
City
Peoria
State/Province
Illinois
Country
United States
City
Kansas City
State/Province
Kansas
Country
United States
City
New Orleans
State/Province
Louisiana
Country
United States
City
Boston
State/Province
Massachusetts
Country
United States
City
St. Louis
State/Province
Missouri
Country
United States
City
Albany
State/Province
New York
Country
United States
City
New York
State/Province
New York
Country
United States
City
Durham
State/Province
North Carolina
Country
United States
City
Philadelphia
State/Province
Pennsylvania
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
City
Memphis
State/Province
Tennessee
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
Temple
State/Province
Texas
Country
United States
City
Salt Lake City
State/Province
Utah
Country
United States
City
Charlottesville
State/Province
Virginia
Country
United States
City
Seattle
State/Province
Washington
Country
United States
City
Vancouver
State/Province
Washington
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms

We'll reach out to this number within 24 hrs